CommercialCoverageMedium impact
Gene Expression Profile Testing and Circulating Tumor DNA Testing for Predicting Recurrence in Colon Cancer
Blue Cross & Blue Shield of Mississippi·MS · Oncology, Gastroenterology, General Surgery·Medical Policy
We identified it
Jun 20, 2026
Summary
BCBS Mississippi policy A.2.04.61 declares gene expression profile testing (Oncotype DX colon cancer test) and circulating tumor DNA assays for predicting colon cancer recurrence in stage 2 or 3 patients as investigational and not covered. This affects billing for genetic testing in colon cancer patients following surgery.
Action Required
Immediately: Billing team must verify coverage before submitting claims for Oncotype DX colon cancer tests and ctDNA testing for colon cancer recurrence prediction. Do not bill these services to BCBS Mississippi as they are considered investigational and will be denied. Update encounter forms to alert providers that these tests are not covered by this payer.